Is diosmin safe for kidneys?

When evaluating​​​​​​​ diosmin powder for an ingredient formulation, kidney safety is a reasonable question, particularly when the intended users may already have reduced renal function. Hongda Phytochemistry, operated by shaanxi hongda phytochemistry co., ltd., supplies diosmin powder for pharmaceutical and supplement manufacturing. However, product quality and clinical safety are two different questions. Current evidence does not justify describing diosmin as a kidney-protective ingredient or claiming that it is universally safe for people with kidney disease. What the available research does show is that diosmin has been studied clinically, and some human safety studies have not identified meaningful changes in routine renal laboratory parameters at the doses investigated.

What Current Evidence Says About Diosmin and the Kidneys?

Diosmin is a flavonoid glycoside related to citrus-derived chemicals and is most studied for venous problems. Following oral treatment, diosmin is quickly transformed into diosmetin in the colon and then metabolized to conjugated forms. In human pharmacokinetic studies, significant levels of unmodified diosmin have not been found in circulation, but diosmetin and its metabolites have.

That difference is significant when talking about kidney safety. The presence of a chemical or its metabolites in the urine does not necessarily imply harm to the kidney. In previous human pharmacokinetic research, unmodified diosmin and diosmetin were not identified in urine, and minimal metabolites were removed by this route.

In a further clinical safety investigation, 327 patients took micronized diosmin at 1,000 or 2,000 mg per day for four months. The researchers found no significant urea, creatinine, or urinalysis abnormalities or major adverse events in the therapy groups. These data are useful but should not be construed to mean that diosmin has no effect on kidney function in all populations or at all doses.

How Is Diosmin Processed After Oral Administration?

The topic of the kidney becomes intelligible when metabolism is understood. Diosmin is hydrolyzed to diosmetin in the gastrointestinal tract. Diosmetin is then transformed to glucuronide conjugates and other metabolites. In human research, following oral administration of 450 mg, diosmetin-3-O-glucuronide was discovered as a significant circulating and urine metabolite.

This finding is consistent with diosmin being a molecule that undergoes extensive metabolism prior to excretion and does not show accumulation of unmodified diosmin in the kidneys.

This also implies that statements on “kidney burden” should be made with caution in view of the existing pharmacokinetic research. At present there is no convincing evidence of an undue effect on normal kidney function of diosmin powder, but this observation cannot be used as a guarantee in persons with advanced renal impairment.

What Human Safety Studies Tell Us

One of the most significant pieces of data to the issue ‘Is diosmin safe for kidneys?’ is derived from clinical safety studies rather than laboratory or animal experiments.

In the 327-patient research cited above, patients were treated with micronized diosmin in doses of up to 2000 mg/day for 4 months. Pre-treatment and follow-up measurements were urea, creatinine, and urinalysis. No significant anomalies of these measures were noted by the investigators.

A previous long-term safety evaluation of Daflon (a formulation of diosmin and hesperidin) also found no significant effect on renal laboratory markers throughout therapy of up to one year.

These studies give useful human safety data but have limitations. The investigations were performed in selected patient populations and under defined dosage conditions. They do not show that all bulk diosmin powder products will be the same, and they do not show safety in patients with severe chronic kidney disease, those who depend on dialysis, or those on complex prescription regimens.

Why Normal Kidney Results Do Not Equal a Universal Guarantee?

Many variables, such as age, underlying disease, hydration condition, concomitant drugs, etc., might alter kidney function. Therefore, a study reporting steady levels of creatinine or urea in one cohort should not be directly extrapolated to persons with markedly variable renal function.

This is particularly the case with an ingredient such as diosmin powder that will be developed for a product that will be sold to the general consuming public. Formulators must differentiate evidence derived in healthy adults, evidence derived in patients with venous problems, and evidence especially derived in those with reduced renal function.

What About Diosmin and Kidney Disease?

Research into diosmin and renal illness is expanding; however, the information specific to the kidney is mainly preclinical.

Diosmin has been studied in animal models of chemically induced kidney injury and inflammatory kidney injury. For instance, a study conducted in 2026 assessed diosmin in rats subjected to cyclophosphamide and observed alterations in renal tissue indicators and inflammatory pathways in the diosmin-treated group.

Such findings are worthy of future study, but not to be sold as evidence for diosmin’s prevention or treatment of renal disease in humans. Animal dosages, metabolism, illness models, and treatment conditions may be very different from those in human clinical use.

The same distinction holds true for research involving oxidative stress, inflammatory signaling, fibrosis, or other biological pathways. Demonstrating an effect on a route in an experimental animal does not necessarily translate into a clinically meaningful renal benefit.

Kidney Stones, Diabetes, and Other Renal Claims

The original article also linked diosmin to the prevention of kidney stones, diabetic kidney disease, the advancement of chronic kidney disease, and protection during cancer therapy. These sections exceeded the strength of evidence available for a consumer-facing safety article.

If there is research in the laboratory or animal models that demonstrates that diosmin or diosmetin impacts a specific kidney system, then that can be mentioned as a potential avenue for further exploration. But it should not be transformed into a claim that diosmin powder can prevent kidney stones, reduce chronic kidney disease, protect diabetic kidneys, or prevent chemotherapy-related renal harm.

This distinction is particularly essential for B2B ingredient content, since downstream manufacturers rely on statements that are backed up by proof that supports the finished formulation.

When Should Kidney Function Receive Extra Attention?

Data from subjects with normal renal function should not be assumed to be immediately applicable to patients with known renal impairment. Chronic renal disease changes the disposition of drugs and other chemicals, and the extent of the impairment changes the disposition of substances.

Given this, patients with known kidney disease, especially those with advanced disease or on dialysis, should speak with a certified healthcare expert regarding diosmin use rather than accept a generic statement that the chemical is “kidney safe.”

The same holds true when diosmin is used with several prescription drugs. The question is not only whether diosmin itself has been linked to aberrant renal test values. Researchers and healthcare professionals may also have to assess the whole drug and supplement profile of the individual.

How to Evaluate the Quality of Diosmin Powder?

For producers acquiring bulk diosmin powder, raw material quality is a key part of responsible formulation. A specification should specify the substance properly and provide suitable information on analysis rather than a generic statement of purity.

HPLC testing can be performed to determine the amount of diosmin. Other quality-control measures can include residual solvents, heavy metals, pesticide residues, microbiological parameters, moisture, and physical features. The right testing package will rely on the application and any relevant regulatory requirements.

Hongda Phytochemistry asserts that the diosmin material is generated by HPLC standardization, and the specifications for 90% diosmin material are shown in its published product information. Buyers should seek the current specification and the batch-specific Certificate of Analysis, rather than believing that specifications listed on a generic webpage apply to every lot.

What B2B Buyers Should Request?

A serious bulk-ingredient evaluation should begin with documentation. Buyers can request the current Certificate of Analysis, specification sheet, identification method, purity test method, microbiological results, heavy-metal results, residual-solvent information where relevant, packaging details, and storage conditions.

It is also useful to clarify whether the quoted specification refers to a standard 90% material or another grade. This avoids a common purchasing problem in which two suppliers use the same ingredient name while offering materials with different specifications.

For diosmin powder, the objective is therefore not simply to find the highest advertised purity. The more useful approach is to match the analytical specification, documentation, manufacturing controls, and intended application.

A Practical Interpretation of Diosmin Kidney Safety

Based on available human studies, there is some evidence that diosmin use at studied doses has not produced significant changes in routine renal markers such as creatinine and urea.

At the same time, the evidence does not support describing diosmin as a proven kidney-protective treatment. Some renal findings come from animal or experimental studies, and these results should remain clearly separated from human clinical evidence.

For this reason, a balanced answer to “Is diosmin safe for kidneys?” is that available human safety data are generally reassuring under the conditions studied, but they do not establish universal safety for people with significant kidney impairment. The quality of the actual ingredient and the circumstances in which it is used also matter.

Conclusion

Current evidence provides a reasonable basis for describing diosmin as having a generally acceptable safety record in the human studies available, including studies in which routine kidney-related laboratory parameters remained stable during the investigated treatment periods. However, this should not be expanded into an unsupported claim that diosmin protects the kidneys or treats kidney disease. Most kidney-specific protective findings remain experimental, while direct clinical evidence in people with substantial renal impairment is limited.

For manufacturers evaluating diosmin powder, the practical priority is to verify the identity, purity, analytical specification, batch documentation, and quality-control procedures of the supplied material. Hongda Phytochemistry and shaanxi hongda phytochemistry co., Ltd. provide diosmin material information for bulk buyers, while purchasers should review the current technical documentation and Certificate of Analysis for the specific batch before formulation.

As a bulk ingredient supplier, Shaanxi Hongda Phytochemistry Co., Ltd. can provide diosmin powder specifications for manufacturers assessing raw materials for pharmaceutical or supplement formulations. Rather than relying on broad “kidney safe” marketing language, buyers can make a more informed assessment by matching the documented product specification with the intended application and the evidence available for diosmin.

Contact us at duke@hongdaherb.com for detailed product specifications, pricing information, and technical support from our experienced team.

References

1. Anwer MK, Aldawsari MF, Alalaiwe A, et al. Nephroprotective Effect of Diosmin against Cisplatin-Induced Kidney Damage by Modulating IL-1β, IL-6, TNFα and Renal Oxidative Damage. Molecules, 2023.

2. Zhang Y, Chen X, Liu J, et al. Diosmin ameliorates renal fibrosis through inhibition of inflammation by regulating SIRT3-mediated NF-κB p65 nuclear translocation. BMC Complementary Medicine and Therapies, 2024.

3. Thummala S, Kadiri SK, Perla S. Dual modulatory effects of diosmin on calcium oxalate kidney stone formation processes. Biomedicine & Pharmacotherapy, 2021.

4. Elhelaly AE, AlBasher G, Alfarraj S, et al. Diosmin Modulates the NF-kB Signal Transduction Pathways and Downregulation of Various Oxidative Stress Markers in Alloxan-Induced Diabetic Nephropathy. International Journal of Pharmacology, 2016.